Next Article in Journal
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
Next Article in Special Issue
ARM’s Perspective on the First Joint Clinical Assessments for ATMPs: Challenges and Opportunities on the Path Ahead
Previous Article in Journal / Special Issue
Ensuring the Efficiency and Effectiveness of Joint Clinical Assessment in National HTA Decision-Making: Insights from the 2024 CIRS Multi-Stakeholder Workshop
 
 
Opinion

Article Versions Notes

J. Mark. Access Health Policy 2025, 13(1), 10; https://doi.org/10.3390/jmahp13010010
Action Date Notes Link
article xml file uploaded 4 March 2025 11:30 CET Original file -
article xml uploaded. 4 March 2025 11:30 CET Update https://www.mdpi.com/2001-6689/13/1/10/xml
article pdf uploaded. 4 March 2025 11:30 CET Version of Record https://www.mdpi.com/2001-6689/13/1/10/pdf
article html file updated 4 March 2025 11:32 CET Original file https://www.mdpi.com/2001-6689/13/1/10/html
Back to TopTop